PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “bone marrow donors”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2025

Analysis of HLA Allelic and Haplotypic Frequencies in a Cohort of Bone Marrow Donors in Catalonia: Impact of Next-Generation Sequencing on Donor Registry Quality.

In haematopoietic stem cell transplantation (HSCT), the volunteer unrelated donor (VUD) has become the most common strategy in Europe, as improved outcomes are achieved through HLA compatibility at allelic-level resolution. In this context, the implementation of next-generation sequencing (NGS) in histocompatibility typing laboratories has significantly enhanced the quality of bone marrow registries, enabling a high level of resolution at a lower cost and improved performance. In this study, we analyse a large cohort of 21,787 bone marrow donors in Catalonia and present the observed HLA allelic and haplotypic frequencies, along with their linkage disequilibria. HLA-A, -B, -C, -E and -G were genotyped at full resolution, while -DRB1, -DQB1, -DQA1, -DPA1 and -DPB1 were genotyped at high resolution. We identified 236 new officially named HLA alleles, both coding and non-coding regions. This study highlights that the implementation of high-throughput HLA typing has led to an increase in the number of registered donors and an improvement in quality, which has been reflected in a rise in the number of effective donors.

Humans↗
PubMed1976

Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt.

Nonspecific immunosuppression of transplant patients frequently leads to complications which might be circumvented by inducing donor-specific immune unresponsiveness. Such specific immunosuppression has been produced experimentally, with use of donor antigen and antilymphocyte serum (ALS) for active enhancement. A case is presented in which the recipient of a cadaveric renal allograft (zero antigen match, cross-match negative) was given ALS (first 14 days after operation) and 11 X 10(9) donor bone marrow cells (twenty-fifth postoperative day) along with conventional doses of prednisone and Imuran in an attempt to produce donor-specific immune unresponsiveness. There were no rejection episodes, and serum creatinine remained less than 1.0 mg. per 100 ml. By the second month after transplantation there was no evidence for the persistence of donor erythrocytes or white cells. The conventional immunosuppressive agents were tapered and renal function was normal 8 months after transplantation, when the patient developed fatal peritonitis secondary to perforated sigmoid diverticulitis. At autopsy the renal allograft showed only minimal evidence of rejection. The present case illustrates an attempt to use ALS and donor bone marrow cells for active enhancement of a human cadaveric renal allograft. The infusion of stored donor marrow cells after transplantation is a particularly applicable technique for human cadaveric organ transplantation. The rejection-free course of this patient suggests that attempts to produce active enhancement clinically deserve further trial.

Adult↗
PubMed1977

The effect of cyclophosphamide on the splecific unresponsiveness to skin allografts induced in ALS-treated mice infused with donor bone marrow.

Specific unresponsiveness to skin allografts can be induced in ALS-treated mice by the injection of bone marrow from the graft-donor strain. Mice bearing long-term grafts in perfect condition have evidence of cell-mediated immunity against donor antigens and also serum-blocking factors. The effect of cyclophosphamide on graft prolongation was investigated in this model. Cyclophosphamide was given either before or after marrow. Cyclophosphamide given before marrow abrogated the enhancing effect of marrow possibly due to a depletion of antibody-forming cells. Cyclophosphamide given after marrow potentiated the effect of marrow probably due to the destruction of immunocompetent cells responding to the challenge of marrow.

Animals↗